Pre-market Movers In Healthcare Sector: APM, TTOO, BCRX, ZSAN, BNTX...

stockmarkets dec12 01sep20 lt

What's moving these stocks in the pre-market hours today?

In the Green

1. Aptorum Group Limited (APM) is up more than 30% at $2.65 in pre-market trading Tuesday, following business update and financial results for the six months ended June 30, 2020. The net loss narrowed to $7.0 million for the six months ended June 30, 2020, compared to $9.6 million for the same period in 2019, thanks to a decline in interest expenses.

2. T2 Biosystems Inc. (TTOO) is up more than 12% at $1.76, following the FDA's Emergency Use Authorization for its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel.

3. BioCryst Pharmaceuticals Inc. (BCRX) is up over 11% at $4.61 in pre-market hours today, adding to yesterday's gain of more than 4%. Yesterday, the National Institute of Allergy and Infectious Diseases awarded the company a new contract totaling $44 million to advance Galidesivir, a broad-spectrum antiviral drug in development for the treatment of COVID-19. Galidesivir is under a phase 1 trial in patients with COVID-19.

4. Calliditas Therapeutics AB (publ) (CALT) is up over 5% at $24.07 in pre-market hours on no news. The company agreed to acquire a controlling interest in Genkyotex SA, a leader in NOX inhibition therapies, last month, with an expected closing in October 2020.

In the Red

1. Zosano Pharma Corporation (ZSAN) is down over 14% at $1.39 in pre-market hours Tuesday, following a proposed public offering of its common stock.

2. Acorda Therapeutics Inc. (ACOR) is down over 6% at $0.51 in pre-market hours today. In the second quarter ended June 30, 2020, the results of which were reported last month, the company generated total revenue of $33.62 million compared to $50 million in the year-ago quarter. However, net loss shrunk to $17.4 million or $0.37 per share from $27.5 million or $0.58 per share in the year-earlier period.

3. BioNTech SE (BNTX) is down over 3% at $58.96 in pre-market trading today, adding to yesterday's loss of more than 4%. A pivotal Phase 2b/3 trial for the BNT162b2 COVID-19 vaccine is underway. The company is targeting filing for emergency authorization or approval of the vaccine as early as October if the trial results are positive.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT